These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 30011788)

  • 21. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
    Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
    JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia.
    Verbeek R; Stoekenbroek RM; Hovingh GK
    Eur J Pharmacol; 2015 Sep; 763(Pt A):38-47. PubMed ID: 25989132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inclisiran-Silencing the Cholesterol, Speaking up the Prognosis.
    Rogula S; Błażejowska E; Gąsecka A; Szarpak Ł; Jaguszewski MJ; Mazurek T; Filipiak KJ
    J Clin Med; 2021 Jun; 10(11):. PubMed ID: 34199468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective.
    Momtazi-Borojeni AA; Pirro M; Xu S; Sahebkar A
    Curr Med Chem; 2022; 29(6):980-999. PubMed ID: 34711156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology.
    Mahmood T; Shapiro MD
    Curr Opin Cardiol; 2019 Sep; 34(5):519-525. PubMed ID: 31246589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacology of PCSK9 Inhibitors: Current Status and Future Perspectives.
    Tsouka AN; Tellis CC; Tselepis AD
    Curr Pharm Des; 2018; 24(31):3622-3633. PubMed ID: 30317986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control.
    Rikhi R; Shapiro MD
    Eur Cardiol; 2023; 18():e45. PubMed ID: 37456766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1.
    Landmesser U; Haghikia A; Leiter LA; Wright RS; Kallend D; Wijngaard P; Stoekenbroek R; Kastelein JJ; Ray KK
    Cardiovasc Res; 2021 Jan; 117(1):284-291. PubMed ID: 32243492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol.
    Wang Y; Liu ZP
    Mini Rev Med Chem; 2019; 19(2):165-176. PubMed ID: 29692249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects.
    Katzmann JL; Gouni-Berthold I; Laufs U
    Front Physiol; 2020; 11():595819. PubMed ID: 33304274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Application of Peptide Nucleic Acids (PNA) in the Inhibition of Proprotein Convertase Subtilisin/Kexin 9 (
    Polak A; Machnik G; Bułdak Ł; Ruczyński J; Prochera K; Bujak O; Mucha P; Rekowski P; Okopień B
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
    Ray KK; Landmesser U; Leiter LA; Kallend D; Dufour R; Karakas M; Hall T; Troquay RP; Turner T; Visseren FL; Wijngaard P; Wright RS; Kastelein JJ
    N Engl J Med; 2017 Apr; 376(15):1430-1440. PubMed ID: 28306389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
    Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
    Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus.
    Rakocevic J; Dobric M; Vucic R; Furtula M; Zaletel I; Milutinovic K; Ilijevski A; Borovic ML; Tomasevic M; Bajcetic M
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PCSK9 inhibition in the management of familial hypercholesterolemia.
    Ogura M
    J Cardiol; 2018 Jan; 71(1):1-7. PubMed ID: 28784313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies.
    Brandts J; Ray KK
    Curr Opin Lipidol; 2020 Aug; 31(4):182-186. PubMed ID: 32487819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PCSK9 Inhibition and Atherosclerosis: Current Therapeutic Option and Prospection.
    Pandey P; Zhao C; Liu B
    Methods Mol Biol; 2020; 2204():133-143. PubMed ID: 32710321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K
    Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.